Achal Patel, Mercer University College of Pharmacy
It is reported that migraines are the third most prevalent illness in the world, prominently affecting women.  Symptoms include visual disturbances, extreme sensitivity to sound, light, touch, and smell, and tingling or numbness in the extremities and face.  Migraines can be classified as either episodic (< 15 headache days/month) or chronic (≤ 15 headache days/month). 
Erenumab is a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor that is involved in migraine pathophysiology through nociceptive mechanisms in the trigeminovascular system.  In a prior phase two trial, erenumab has shown a reduction in the number of episodic migraines at monthly doses of 70 mg and 140 mg.